Improvement of genetic stability in lymphocytes from Fanconi anemia patients through the combined effect of -lipoic acid and N-acetylcysteine

Orphanet Journal of Rare Diseases

Volumn 7, Issue 1, 2012, Pages

  Ponte, Filipa ^a   Sousa, Rosa ^a   Fernandes, Ana Paula ^b   Gonçalves, Cristina ^c   Barbot, José ^d   Carvalho, Félix ^a   Porto, Beatriz ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c Institute of Biomedical Sciences Abel Salazar   (Portugal)

^d Unity of Pediatric Hematology of CHP   (Portugal)

Author keywords

lipoic acid; Antioxidants; Bone marrow failure; Cancer susceptibility; Chromosome instability; Fanconi Anemia; N acetylcysteine; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; GLUTATHIONE SYNTHASE; THIOCTIC ACID; ANTIOXIDANT;

ARTICLE; BONE MARROW; CELL CULTURE; CHIMERA; CHROMOSOMAL INSTABILITY; CHROMOSOME BREAKAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EXPOSURE; FANCONI ANEMIA; GENETIC STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE; METAPHASE; NEOPLASM; PROPHYLAXIS; ADULT; DRUG EFFECT; FEMALE; GENETICS; MALE; METABOLISM; OXIDATIVE STRESS;

ACETYLCYSTEINE; ADULT; ANTIOXIDANTS; CELLS, CULTURED; CHROMOSOMAL INSTABILITY; FANCONI ANEMIA; FEMALE; HUMANS; LYMPHOCYTES; MALE; OXIDATIVE STRESS; THIOCTIC ACID; YOUNG ADULT;

EID: 84861000048     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-7-28     Document Type: Article

References (54)

1. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, Hanenberg H, Auerbach AD, Blood 2003 101 1249 1256 10.1182/blood-2002-07-2170 12393516 (Pubitemid 36182492)
2. Mutations of the SLX4 gene in Fanconi anemia. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A, Nat Genet 2011 43 142 146 10.1038/ng.750 21240275
3. Fanconi anemia and its diagnosis. Auerbach AD, Mutat Res/Fundam Mol Mech Mutagenesis 2009 668 4 10 10.1016/j.mrfmmm.2009.01.013
4. Oxidative stress in Fanconi anaemia: from cells and molecules toward prospects in clinical management. Pagano G, Aiello Talamanca A, Castello G, Pallardá FV, Zatterale A, Degan P, Biol Chem In press.
5. Redox-dependent toxicity of diepoxybutane and mitomycin C in sea urchin embryogenesis. Korkina LG, Deeva IB, De Biase A, Iaccarino M, Oral R, Warnau M, Pagano G, Carcinogenesis 2000 21 213 220 10.1093/carcin/21.2.213 10657960 (Pubitemid 30098705)
6. GSTT1-dependent induction of centromere-negative and -positive micronuclei by 1,2:3,4-diepoxybutane in cultured human lymphocytes. Vlachodimitropoulos D, Norppa H, Autio K, Catalan J, Hirvonen A, Tasa G, Uuskula M, Demopoulos NA, Sorsa M, Mutagenesis 1997 12 397 403 10.1093/mutage/12.5.397 9379921 (Pubitemid 27417581)
7. Diepoxybutane cytotoxicity on mouse germ cells is enhanced by in vivo glutathione depletion: a flow cytometric approach. Spano M, Cordelli E, Leter G, Pacchierotti F, Mutat Res-Fund Mol M 1998 397 37 43 10.1016/S0027-5107(97) 00193-0 (Pubitemid 28053753)
8. Diepoxybutane activates the mitochondrial apoptotic pathway and mediates apoptosis in human lymphoblasts through oxidative stress. Yadavilli S, Martinez-Ceballos E, Snowden-Aikens J, Hurst A, Joseph T, Albrecht T, Muganda PM, Toxicology in Vitro 2007 21 1429 1441 10.1016/j.tiv.2007.06.007 17693053 (Pubitemid 350086863)
9. DNA protein cross-linking by 1,2,3,4-diepoxybutane. Michaelson-Richie ED, Loeber RL, Codreanu SG, Ming X, Liebler DC, Campbell C, Tretyakova NY, J Proteome Res 2010 9 4356 4367 10.1021/pr1000835 20666492
10. Protective effect of acetyl-l-carnitine and -lipoic acid against the acute toxicity of diepoxybutane to human lymphocytes. Ponte F, Carvalho F, Porto B, Toxicology 2011 289 52 58 10.1016/j.tox.2011.07.009 21807063
11. Effect of superoxide dismutase and catalase on spontaneously occurring chromosome breaks in patients with Fanconi's anemia. Nordenson I, Hereditas 1977 86 147 150 914646 (Pubitemid 8224367)
12. Oxygen-dependence of chromosomal aberrations in Fanconi's anaemia. Joenje H, Arwert F, Eriksson AW, de Koning H, Oostra AB, Nature 1981 290 142 143 10.1038/290142a0 7207594 (Pubitemid 11149688)
13. Effect of oxygen tension on chromosomal aberrations in Fanconi anaemia. Joenje H, Oostra B, Hum Genet 1983 65 99 101 10.1007/BF00286642 6418637 (Pubitemid 14210624)
14. Abnormal microsomal detoxification implicated in Fanconi anemia group C by interaction of the FAC protein with NADPH cytochrome P450 reductase. Kruyt FAE, Hoshino T, Liu JM, Joseph P, Jaiswal AK, Youssoufian H, Blood 1998 92 3050 3056 9787138 (Pubitemid 28492309)
15. Fanconi anemia group C protein prevents apoptosis in hematopoietic cells through redox regulation of GSTP1. Cumming RC, Lightfoot J, Beard K, Youssoufian H, O'Brien PJ, Buchwald M, Nat Med 2001 7 814 820 10.1038/89937 11433346 (Pubitemid 32691636)
16. The FANCG Fanconi anemia protein interacts with CYP2E1: possible role in protection against oxidative DNA damage. Futaki M, Igarashi T, Watanabe S, Kajigaya S, Tatsuguchi A, Wang J, Liu JM, Carcinogenesis 2002 23 67 72 10.1093/carcin/23.1.67 11756225 (Pubitemid 34213553)
17. Mitochondrial alterations in Fanconi anemia fibroblasts following ultraviolet A or psoralen photoactivation. Rousset S, Nocentini S, Rouillard D, Baroche C, Moustacchi E, Photochem Photobiol 2002 75 159 166 10.1562/0031-8655(2002)075<0159:MAIFAF>2.0.CO;2 11883604
18. Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia. Mukhopadhyay SS, Leung KS, Hicks MJ, Hastings PJ, Youssoufian H, Plon SE, J Cell Biol 2006 175 225 235 10.1083/jcb.200607061 17060495 (Pubitemid 44631417)
19. In vivo accumulation of 8-hydroxy-2'-deoxyguanosine in DNA correlates with release of reactive oxygen species in Fanconi's anaemia families. Degan P, Bonassi S, Caterina MD, Korkina LG, Pinto L, Scopacasa F, Zatterale A, Calzone R, Pagano G, Carcinogenesis 1995 16 735 742 10.1093/carcin/16.4.735 7728950
20. Coordinated action of the Fanconi anemia and ataxia telangiectasia pathways in response to oxidative damage. Castillo P, Bogliolo M, Surralles J, DNA Repair 2011 10 518 525 10.1016/j.dnarep.2011.02.007 21466974
21. Effect of oxidants and antioxidants on chromosomal breakage in Fanconi anemia lymphocytes. Dallapiccola B, Porfirio B, Mokini V, Alimena G, Isacchi G, Gandini E, Hum Genet 1985 69 62 65 10.1007/BF00295530 3967890 (Pubitemid 15153914)
22. Partial correction of chromosome instability in Fanconi anemia by desferrioxamine. Porfirio B, Ambroso G, Giannella G, Isacchi G, Dallapiccola B, Hum Genet 1989 83 49 51 10.1007/BF00274146 2767678 (Pubitemid 19206041)
23. Fanconi anemia lymphocytes: effect of dl - tocopherol (Vitamin E) on chromatid breaks and on G2 repair efficiency. Pincheira J, Bravo M, Santos MJ, de la Torre C, Lápez-Sáez JF, Mutat Res 2001 461 265 271 10.1016/S0921-8777(00)00058-6 11104902
24. Tempol protects against oxidative damage and delays epithelial tumor onset in Fanconi anemia mice. Zhang Q-S, Eaton L, Snyder ER, Houghtaling S, Mitchell JB, Finegold M, Van Waes C, Grompe M, Cancer Res 2008 68 1601 1608 10.1158/0008-5472.CAN-07-5186 18316625 (Pubitemid 351346870)
25. Fancd2/ mice have hematopoietic defects that can be partially corrected by resveratrol. Zhang Q-S, Marquez-Loza L, Eaton L, Duncan AW, Goldman DC, Anur P, Watanabe-Smith K, Rathbun RK, Fleming WH, Bagby GC, Grompe M, Blood 2010 116 5140 5148 10.1182/blood-2010-04-278226 20826722
26. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies. Tarnopolsky MA, Adv Drug Deliv Rev 2008 60 1561 1567 10.1016/j.addr.2008.05.001 18647623
27. Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome. Pallardá F, Lloret A, Lebel M, dIschia M, Cogger V, Le Couteur D, Gadaleta M, Castello G, Pagano G, Biogerontology 2010 11 401 419 10.1007/s10522-010-9269-4 20237955
28. Salubrious effects of lipoic acid against adriamycin-induced clastogenesis and apoptosis in Wistar rat bone marrow cells. Prahalathan C, Selvakumar E, Varalakshmi P, Kumarasamy P, Saravanan R, Toxicology 2006 222 225 232 10.1016/j.tox.2006.02.015 16580770
29. Intervention of -lipoic acid ameliorates methotrexate-induced oxidative stress and genotoxicity: a study in rat intestine. Dadhania VP, Tripathi DN, Vikram A, Ramarao P, Jena GB, Chem Biol Interact 2010 183 85 97 10.1016/j.cbi.2009.10.020 19900424
30. Clinical applications of N-acetylcysteine. Kelly GS, Altern Med Rev 1998 3 114 127 9577247 (Pubitemid 128709607)
31. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. Mantovani G, Macci A, Madeddu C, Mura L, Gramignano G, Lusso M, Massa E, Mocci M, Serpe R, J Mol Med 2003 81 664 673 10.1007/s00109-003-0476-1 12928788 (Pubitemid 37357681)
32. The comparison of antioxidant and hematological properties of N-acetylcysteine and alpha-lipoic acid in physically active males. Zembron-Lacny A, Slowinska-Lisowska M, Szygula Z, Witkowski K, Szyszka K, Physiol Res 2009 58 855 861 19093729
33. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization. Han D, Handelman G, Marcocci L, Sen CK, Roy S, Kobuchi H, Tritschler HJ, Flohe L, Packer L, Biofactors 1997 6 321 338 10.1002/biof.5520060303 9288403 (Pubitemid 27487808)
34. Plasma kinetics, metabolism, and urinary excretion of Alpha-Lipoic acid following oral administration in healthy volunteers. Teichert J, Hermann R, Ruus P, Preiss R, J Clin Pharmacol 2003 43 1257 1267 10.1177/0091270003258654 14551180 (Pubitemid 37280797)
35. Pharmacokinetics of intravenous <i>N -acetylcysteine in men at rest and during exercise. Brown M, Bjorksten A, Medved I, McKenna M, Eur J Clin Pharmacol 2004 60 717 723 10.1007/s00228-004-0862-9 15619135
36. Glutathione regulates susceptibility to oxidant-induced mitochondrial DNA damage in human lymphocytes. Hollins DL, Suliman HB, Piantadosi CA, Carraway MS, Free Radic Biol Med 2006 40 1220 1226 10.1016/j.freeradbiomed.2005.11.011 16545690
37. Gender- and age-related distinctions for the in vivo prooxidant state in Fanconi anaemia patients. Pagano G, Degan P, d'Ischia M, Kelly FJ, Pallardá FV, Zatterale A, Anak SS, Akik EE, Beneduce G, Calzone R, et al. Carcinogenesis 2004 25 1899 1909 10.1093/carcin/bgh194 15192013 (Pubitemid 39405909)
38. The 5-GNC site for DNA interstrand cross-linking is conserved for Diepoxybutane Stereoisomers. Millard JT, Hanly TC, Murphy K, Tretyakova N, Chem Res Toxicol 2005 19 16 19 (Pubitemid 43185457)
39. Fanconi Anemia. Alter B, Kupfer G, GeneReviews University of Washington, Seattle, Seattle, Pagon RA, Bird TD, Dolan CR, Stephens K, 2011
40. Fatal course of tonsillar squamous cell carcinoma associated with Fanconi anaemia: A mini review. Spanier G, Pohl F, Giese T, Meier JK, Koelbl O, Reichert TE, J Craniomaxillofac Surg In press.
41. Is -lipoic acid a scavenger of reactive oxygen species in vivo? Evidence for its initiation of stress signaling pathways that promote endogenous antioxidant capacity. Shay K, Moreau RF, Smith EJ, Hagen TM, IUBMB Life 2008 60 362 367 10.1002/iub.40 18409172
42. Effects of -Lipoic acid and Dihydrolipoic acid on expression of proto-oncogene c-fos. Mizuno M, Packer L, Biochem Biophys Res Commun 1994 200 1136 1142 10.1006/bbrc.1994.1569 8179594
43. Impaired immune function in children with Fanconi anaemia. Myers KC, Bleesing JJ, Davies SM, Zhang X, Martin LJ, Mueller R, Harris RE, Filipovich AH, Kovacic MB, Wells SI, Mehta PA, Br J Haematol 2011 154 234 240 10.1111/j.1365-2141.2011.08721.x 21542827
44. Impaired function of Fanconi anemia type C-deficient macrophages. Liu Y, Ballman K, Li D, Khan S, Derr-Yellin E, Shou W, Haneline LS, J Leukoc Biol In press.
45. Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor alpha. Rosselli F, Sanceau J, Gluckman E, Wietzerbin J, Moustacchi E, Blood 1994 83 1216 1225 8118026 (Pubitemid 24062844)
46. Allergic and immunologic parameters in patients with Fanconi's anemia. Roxo PJ, Arruda LK, Nagao AT, Carneiro-Sampaio MM, Ferriani VP, Int Arch Allergy Immunol 2001 125 349 355 10.1159/000053837 11574758 (Pubitemid 34701514)
47. N-Acetylcysteinea safe antidote for cysteine/glutathione deficiency. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA, Curr Opin Pharmacol 2007 7 355 359 10.1016/j.coph.2007.04.005 17602868 (Pubitemid 47289259)
48. N-acetylcysteine: multiple clinical applications. Millea PJ, Am Fam Physician 2009 80 265 269 19621836
49. Antioxidant therapy in human endocrine disorders. Golbidi S, Laher I, Med Sci Monit 2010 16 A9 RA24 20037503
50. Lipoic acid-the drug of the future? Bilska A, Wlodek L, Pharmacol Rep 2005 57 570 577 16227639
51. Lipoic acid-the drug of the future? Tolar J, Becker S, Clapp D, Hanenberg H, Heredia C, Kiem H-P, Navarro S, Qasba P, Rio P, Schmidt M, Hum Gene Ther 2012 23 141 144 10.1089/hum.2011.237 22248350
52. Treatment of the bone marrow failure in Fanconi anemia patients with danazol. Scheckenbach K, Morgan M, Filger-Brillinger J, Sandmann M, Strimling B, Scheurlen W, Schindler D, Göbel U, Hanenberg H, Blood Cells Mol Dis 2012 48 128 131 10.1016/j.bcmd.2011.11.006 22178060
53. Scientific evidence to support a vitamin e and heart disease health claim: research needs. Jialal I, Devaraj S, J Nutr 2005 135 348 353 15671241 (Pubitemid 40194506)
54. Effects of long-term vitamin e supplementation on cardiovascular events and cancer: a randomized controlled trial. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold J, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais G, JAMA 2005 293 1338 1347 15769967 (Pubitemid 40381486)